Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for IRBESARTAN
- Feasibility of Aggressive Albuminuria Reduction in Biopsy-Proven Diabetic Nephropathy - A Pilot Study
- Bioequivalence Study of Two Irbesartan in Healthy Chinese Subjects
- Pharmacokinetics of Irbesartan/Amlodipine High FDC and Co-administration of Irbesartan and Amlodipine High in Healthy Volunteers
- : Pharmacokinetics of Irbesartan High/Amlodipine FDC and Co-administration of Irbesartan High and Amlodipine in Healthy Volunteers
- Pharmacokinetics of Irbesartan/Amlodipine FDC and Co-administration of Irbesartan and Amlodipine in Healthy Volunteers
- ETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC)
- Clinical Efficacy and Safety Evaluation of Irbesartan and Amlodipine Combined Therapy in Essential Hypertension Patients
- Clinical Efficacy and Safety Evaluation of Irbesartan High and Amlodipine Combined Therapy in Essential Hypertension Patients
- Low-dose Quadruple Combination Therapy in Patients With Hypertension
- A Bioequivalence Trial of Irbesartan Tablets（0.15g） in Healthy Chinese Subjects
- Impact of a Treatment With Angiotensin Receptor Blocker on Outcome After Acute Kidney Injury in Patients Discharged From the ICU.
- Sacubitril/Valsartan for CKD5 Stage Dialysis Patients With Heart Failure
- A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia
- The ORTIZ Study: Optimising RASi Therapy With SZC
- Study on the Efficacy and Safety of a Novel Tripterygium Wilfordii Preparation in Reducing Proteinuria in Patients With Diabetic Nephropathy
- Effect of Losartan or Eprosartan on Fructose Hyperuricemia
- Phase 2 Study to Evaluate the Efficacy and Safety of Irbesartan and Amlodipine Combined or Alone in Patients With Essential Hypetension
- Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease
- Telmisartan for Treatment of COVID-19 Patients
- A Study to Evaluate ALN-AGT01 in Patients With Hypertension
- A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy
- Safety and Effectiveness of Propagermanium in Focal Segmental Glomerulosclerosis Participants Receiving Irbesartan
- Safety and Effectiveness of Propagermanium in Diabetic Kidney Disease Participants Receiving Irbesartan
- Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)
- Clinical Study of Treating Type 2 Diabetic Nephropathy With Alfacalcidol and Irbesartan
- Clinical Trial of HuangKui Capsule to Treat Diabetic Kidney Disease
- Amlodipine Versus Valsartan for Improvement of Diastolic Dysfunction Associated With Hypertension
- Evaluation of the Fixed-dose Combination of Irbesartan/Atorvastatin in Type 2 Diabetic Patients Diagnosed With Hyperlipidemia and Hypertension
- A Prospective, Single-center, Randomized, Controlled Study of Sevelamer Carbonate in the Lipid Metabolism and Uric Acid Treatment of Obesity-Related Glomerulopathy
- Angiotensin II Receptor Blockade in Vascular Ehlers Danlos Syndrome (ARCADE)
- Effectiveness of Avapro in Obese Normotensive/Hypertensive African Americans
- Proteomic Prediction and Renin Angiotensin Aldosterone System Inhibition Prevention Of Early Diabetic nephRopathy In TYpe 2 Diabetic Patients With Normoalbuminuria
- Angiotensin II Antagonist in Severe Sepsis
- The Oxford Marfan Trial
- Drug Interaction Between Irbesartan and Hydrochlorothiazide
- Pharmacokinetic Drug Interaction Study Between Gemigliptin and Irbesartan After Oral Administration in Healthy Male Subjects
- Comparison of Aliskiren vs Negative Controls on Aortic Stiffness in Patients With MFS
- Crossover Bioequivalence Study of Irbesartan HCTZ 300/25 mg Tablets Under Fasted Conditions
- Crossover Bioequivalence Study of Irbesartan Hydrochlorothiazide 300/25 mg Tablets Under Fed Conditions
- Crossover Bioequivalence Study of Irbesartan 300 mg Tablets Under Fasted Conditions
- Crossover Bioequivalence Study of Irbesartan 300 mg Tablets Under Fed Conditions
- A Trial of Fimasartan for Early Diastolic Heart Failure
- Study of Efficacy and Safety of Irbesartan/Amlodipine 4 Fixed Combination Therapy in Hypertensive Patients Uncontrolled on Irbesartan or Amlodipine Monotherapy
- Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
- Preeclampsia: A Marker for Future Cardiovascular Risk in Women
- Effect of Renin-angiotensin System Blockers on Glomerular Filtration Rate in Patients With Hypertension, Type 2 Diabetes With Normoalbuminuria
- A Bioequivalence Study Comparing Irbesartan/Atorvastatin Combination Tablet With Coadministration of Irbesartan and Atorvastatin
- Efficacy and Safety of Irbesartan and Atorvastatin in Hypertension and Hyperlipidemia
- The Effect of Moxonidine on Blood Pressure and Regression of Early Target Organ Damage in Young Subjects With Abdominal Obesity and Hypertension
- Combined Antihypertensive Therapy and Sexual Dysfunction
- Albuminuria Reduction With Renin Angiotensin System Inhibitors in SCA Patients
- The Effects of Bindarit in Diabetic Nephropathy
- Irbesartan Versus Amlodipine: The OBI Study
- Irbesartan/Amlodipine in Hypertensive Patients Uncontrolled on Irbesartan 150 mg Monotherapy
- Irbesartan/Amlodipine in Hypertensive Patients Uncontrolled on Amlodipine 5 mg Monotherapy
- Irbesartan and Amlodipine Combination in Controlling Blood Pressure
- Comparison of Standard Versus Low Dose Advagraf® With or Without Angiotensin-converting Enzyme Inhibitor (ACEi)/Angiotensin Receptor Blocker (ARB) on Histology and Function of Renal Allografts
- The Effects of Peroxisome Proliferators Activated Receptor-Gamma (PPAR-γ) Agonists on Certain Biochemical and Inflammatory Markers in Metabolic Syndrome
- Irbesartan-Hydrochlorothiazide Phase IV Study: Treatment of Hypertension in Chinese Population
- Saving Residual Renal Function Among Haemodialysis Patients Receiving Irbesartan
- Role of AT1-receptor Blockers in Insulin-induced Vasodilation.
- Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment
- Ocsaar and CYP2C9 Ploymorphism, Is There a Connection Between Pharmacokinetics, Pharmacodynamics and Pharmacogenetics?
- Aliskiren's Effect on Arterial Stiffness and Platelet Function in Patients With Diabetes Mellitus (DM)
- ACTUAL: Efficacy and Safety of Irbesartan/Hydrochlorothiazide Combination
- Irbesartan/Hydrochlorothiazide to Control Elevated Blood Pressure to Target in Moderate to Severe Hypertensive Patients
- A Clinical Study to Evaluate Renal Hemodynamic Responses to Aliskiren in Patients With Type 2 Diabetes Mellitus
- Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy (IgAN)
- A Study To Evaluate The Dose-Related Efficacy and Safety of PS433540 in Subjects With Hypertension
- Irbesartan and Adhesion Molecules in AF
- Evaluation of Efficacy and Safety of the Dosage Adjustment of Aprovel® (Irbesartan) in Hypertensive Outpatients in Current Clinical Practice
- The Efficacy and Safety of Irbesartan 150/12.5 mg and 300/25 mg in Patients With Mild Hypertension
- Randomized, Parallel, Comparison, Double-Blind Efficacy & Safety Study of APROVEL Versus Placebo in Chinese Patients With Hypertensive Type II Diabetic Patients With Microalbuminuria
- Irbesartan Effects on Endothelial Dysfunction in Hypertensive Type II Diabetic Patients Comparing Atenolol
- Nephropathy In Type 2 Diabetes and Cardio-renal Events
- Effect of the Angiotensin II Receptor Antagonist Irbesartan on Biochemical and Functional Markers of Endothelial Dysfunction in Patients With Hypertension
- Left Atrial Remodelling in Hypertension: Effects of Ramipril or Irbesartan
- Efficacy of Irbesartan/Hydrochlorothiazide Versus Valsartan/Hydrochlorothiazide in Mild to Moderate Hypertension
- Association Between Rosiglitazone Use and Clinical Course of Diabetic Nephropathy: Population-Based Study
- Effects of Aliskiren, Irbesartan, and the Combination in Hypertensive Patients With Type 2 Diabetes and Diabetic Nephropathy
- Irbesartan/Hydrochlorothiazide National Taiwan University Hospital Listing
- Irbesartan and Atenolol in Hypertensive Heart Disease
- I PREVENT - Irbesartan In Hypertensive Diabetic Patients
- I SELECT - Irbesartan In Hypertensive Patients With Left Ventricular Hypertrophy
- Effects of Losartan on Insulin Sensitivity and Secretion in Type 2 Diabetes and Nephropathy
- Effects of Thiazide Diuretics on Sympathetic Nervous System in Hypertension
- Electrophysiological Effects of Irbesartan in Patients With Paroxysmal Atrial Fibrillation (AF)
- Irbesartan, Ciprofibrate and Their Combination Onto the Endothelial Functions
- Effect of Irbesartan on Insulin Sensitivity in Chronic Heart Failure
- Efficacy and Safety of Aliskiren 300mg Compared to Irbesartan 300mg and Ramipril 10 mg in the Setting of a Missed Dose for Patients With Essential Hypertension.
- I SAVE - Irbesartan in Mild to Moderate Hypertensive Patients
- Irbesartan in Chinese Hypertensive Diabetics With Microalbuminuria
- Angiotensin II Antagonism of TGF-Beta 1
- Optimal Dose of Irbesartan for Renoprotection in Type 2 Diabetic Patients With Persistent Microalbuminuria
- Irbesartan in Type 2 Diabetes
- ARCHIPELAGO: Irbesartan in Patients With Acute Coronary Syndrome Without ST Segment Elevation
- APROVE : Irbesartan in Hypertension
- Irbesartan in Hypertension
- Evaluation of Irbesartan on Hepatic Fibrosis in Chronic Hepatitis C
- AMISH : Aprovel for Management of Isolated Systolic Hypertension
- Irbesartan/Hydrochlorothiazide and Irbesartan in the Treatment of Mild to Moderate Hypertension
- Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE A)
- Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE I)
- Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE W)
- Prevention of Decompensation in Liver Cirrhosis
- Irbesartan for the Prevention of Atrial Arrhythmias and Cardiac Electrical Remodeling in Patients With Hypertension and Permanent Pacemakers
- PHARES Study: Management of Resistant Hypertension
- A Clinical Study to Compare Combination of Aliskiren+ HCTZ to Irbesartan+ HCTZ or Amlodipine+ HCTZ or HCTZ Alone in Obese Hypertensive Not Responsive to HCTZ 25 mg
- High Dose Ace Inhibitor Therapy Versus Combination of ACE and ARB Therapy
- The Relative Effects of Olmesartan Medoxomil, Irbesartan and Valsartan on the Activity of the Blood Pressure Control System in Healthy Subjects
- VALID: Study to Compare the Reduction of Predialysis Systolic Blood Pressure With Valsartan Compared to Irbesartan in Patients With Mild to Moderate Hypertension on Long-term Hemodialysis
- Comparison of Vascular Effects After Therapy With Irbesartan and Atorvastatin.
- Effect of Irbesartan on Endothelial Function of the Retinal Vasculature in Patients With Hypercholesterolemia
- Effect of Sulodexide in Overt Diabetic Nephropathy
- Effect of Sulodexide in Early Diabetic Nephropathy
- Left Ventricular Function After Acute Myocardial Infarction (AMI). Treatment With Angiotensin 2-Receptor Blockade (GLOBAL-Study)
- To Determine the Effects of Avosentan on Doubling of Serum Creatinine, End Stage Renal Disease and Death in Diabetic Nephropathy
- Irbesartan in the Treatment of Hypertensive Patients With Metabolic Syndrome
- Using the Drug Spironolactone to Test If It Reduces Protein Leakage From the Kidney
- Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy for Patients With Moderate Hypertension
- Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy as First Line Treatment for Severe Hypertension
- Irbesartan Versus Placebo in Combination With Ramipril for Treatment of Albuminuria
- Irbesartan in Heart Failure With Preserved Systolic Function (I-Preserve)
- Treatment of Diabetic Nephropathy
- Prevention of Kidney Transplant Rejection
Clinical trials list
click for details